Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
<Group xmlns="http://hl7.org/fhir">
<id value="7750"/>
<meta>
<versionId value="8"/>
<lastUpdated value="2023-12-05T12:59:21.649Z"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Group</b><a name="7750"> </a><a name="hc7750"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceGroup "7750" Version "8" Updated "2023-12-05 12:59:21+0000" </p></div><p><b>Artifact related artifact</b>: </p><p><b>Artifact URL</b>: <a href="https://fevir.net/resources/Group/7750">https://fevir.net/resources/Group/7750</a></p><p><b>Artifact Date</b>: 2022-01-11 17:20:56+0000</p><p><b>Artifact Publisher</b>: Computable Publishing LLC</p><p><b>Artifact Copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>Artifact Contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>CombinationMethod</b>: all-of</p><blockquote><p><b>modifierExtension[http://hl7.org/fhir/StructureDefinition/artifact-status]</b></p></blockquote><p><b>identifier</b>: FEvIR Object Identifier/7750</p><p><b>type</b>: person</p><p><b>membership</b>: enumerated</p><p><b>name</b>: Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill</p><p><b>description</b>: An enumerated group participating in a randomized trial.</p><p><b>quantity</b>: 2244</p><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: Participant in the Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT</p><p><b>code</b>: Research Study for which this is the observed sample <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>value</b>: <a href="Citation-7636.html">Citation/7636: Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Journal Article]. Contributors: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. In: The New England Journal of Medicine, DOI 10.1056/NEJMoa2105911. Published August 04, 2021. Available at: https://doi.org/10.1056/NEJMoa2105911.</a></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: Hospitalized</p><p><b>code</b>: Admission to establishment (procedure) <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://browser.ihtsdotools.org/">SNOWMED CT</a>#305335007)</span></p><p><b>value</b>: Hospital admission <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://browser.ihtsdotools.org/">SNOWMED CT</a>#32485007)</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: COVID-19</p><p><b>code</b>: Disease (disorder) <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://browser.ihtsdotools.org/">SNOWMED CT</a>#64572001)</span></p><p><b>value</b>: ATTACC and ACTIV-4a limited inclusion to patients with confirmed COVID-19 (and excluded initially entered participants who did not have confirmed SARS-CoV-2. REMAP-CAP however included patients with confirmed COVID-19 or suspected COVID-19 with intent to test for COVID-19. <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://browser.ihtsdotools.org/">SNOWMED CT</a>#840539006 "Disease caused by severe acute respiratory syndrome coronavirus 2 (disorder)")</span></p><p><b>exclude</b>: false</p></blockquote><blockquote><p><b>characteristic</b></p><p><b>CharacteristicDescription</b>: not critically ill</p><p><b>code</b>: Severity <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://browser.ihtsdotools.org/">SNOWMED CT</a>#246112005)</span></p><p><b>value</b>: severe disease defined as ICU-level care or critically ill where ICU-level care was defined as the use of respiratory or cardiovascular organ support (oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes) <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://browser.ihtsdotools.org/">SNOWMED CT</a>#442452003 "Life threatening severity")</span></p><p><b>exclude</b>: true</p></blockquote></div>
</text>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
<valueRelatedArtifact>
<type value="cite-as"/>
<citation
value="Participants in Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT (hospitalized, not critically ill) [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 7750. Revised 2022-01-11. Available at: https://fevir.net/resources/Group/7750. Computable resource at: https://fevir.net/resources/Group/7750."/>
</valueRelatedArtifact>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-url">
<valueUri value="https://fevir.net/resources/Group/7750"/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-date">
<valueDateTime value="2022-01-11T17:20:56.687Z"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-publisher">
<valueString value="Computable Publishing LLC"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-copyright">
<valueMarkdown
value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-contact">
<valueContactDetail>
<telecom>
<system value="email"/>
<value value="support@computablepublishing.com"/>
</telecom>
</valueContactDetail>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<name value="Brian S. Alper"/>
</valueContactDetail>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method">
<valueCode value="all-of"/>
</extension>
<modifierExtension
url="http://hl7.org/fhir/StructureDefinition/artifact-status">
<valueCode value="active"/>
</modifierExtension>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="7750"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<type value="person"/>
<membership value="enumerated"/>
<name
value="Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill"/>
<description
value="An enumerated group participating in a randomized trial."/>
<quantity value="2244"/>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown
value="Participant in the Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT"/>
</extension>
<code>
<text value="Research Study for which this is the observed sample"/>
</code>
<valueReference>🔗
<reference value="Citation/7636"/>
<display
value="Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Journal Article]. Contributors: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. In: The New England Journal of Medicine, DOI 10.1056/NEJMoa2105911. Published August 04, 2021. Available at: https://doi.org/10.1056/NEJMoa2105911."/>
</valueReference>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown value="Hospitalized"/>
</extension>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="305335007"/>
<display value="Admission to establishment (procedure)"/>
</coding>
</code>
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="32485007"/>
<display value="Hospital admission"/>
</coding>
</valueCodeableConcept>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown value="COVID-19"/>
</extension>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="64572001"/>
<display value="Disease (disorder)"/>
</coding>
</code>
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="840539006"/>
<display
value="Disease caused by severe acute respiratory syndrome coronavirus 2 (disorder)"/>
</coding>
<text
value="ATTACC and ACTIV-4a limited inclusion to patients with confirmed COVID-19 (and excluded initially entered participants who did not have confirmed SARS-CoV-2. REMAP-CAP however included patients with confirmed COVID-19 or suspected COVID-19 with intent to test for COVID-19."/>
</valueCodeableConcept>
<exclude value="false"/>
</characteristic>
<characteristic>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description">
<valueMarkdown value="not critically ill"/>
</extension>
<code>
<coding>
<system value="http://snomed.info/sct"/>
<code value="246112005"/>
<display value="Severity"/>
</coding>
</code>
<valueCodeableConcept>
<coding>
<system value="http://snomed.info/sct"/>
<code value="442452003"/>
<display value="Life threatening severity"/>
</coding>
<text
value="severe disease defined as ICU-level care or critically ill where ICU-level care was defined as the use of respiratory or cardiovascular organ support (oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes)"/>
</valueCodeableConcept>
<exclude value="true"/>
</characteristic>
</Group>
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2024-05-16
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change